Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
一项前瞻性、多中心队列研究:炎症性肠病患者接种三剂新冠疫苗(VIP)后针对SARS-CoV-2 Omicron BA.4/5和野生型病毒的中和抗体反应
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2023.102249
Liu, Zhigang; Alexander, James L; Le, Kaixing; Zhou, Xin; Ibraheim, Hajir; Anandabaskaran, Sulak; Saifuddin, Aamir; Lin, Kathy Weitung; McFarlane, Leon R; Constable, Laura; Seoane, Rocio Castro; Anand, Nikhil; Bewshea, Claire; Nice, Rachel; D'Mello, Andrea; Jones, Gareth R; Balarajah, Sharmili; Fiorentino, Francesca; Sebastian, Shaji; Irving, Peter M; Hicks, Lucy C; Williams, Horace Rt; Kent, Alexandra J; Linger, Rachel; Parkes, Miles; Kok, Klaartje; Patel, Kamal V; Teare, Julian P; Altmann, Daniel M; Boyton, Rosemary J; Hart, Ailsa L; Lees, Charlie W; Goodhand, James R; Kennedy, Nicholas A; Pollock, Katrina M; Ahmad, Tariq; Powell, Nick